Epcoritamab for Relapsed/Refractory EBV+ Post‐Transplant Lymphoproliferative Disorder of DLBCL‐Type
eJHaem · 2025-12 · 6 (6)
DOI: 10.1002/jha2.70156 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 25.10.2025. Verfasst von Li Yuan Chan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haemato-Oncology The Royal Marsden NHS Foundation Trust Sutton UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background Patients with relapsed/refractory post‐transplant lymphoproliferative disorder (R/R PTLD) following solid‐organ transplants (SOT) or hematopoietic stem cell transplants (HSCT) after frontline chemoimmunotherapy have dismal outcomes. There is no standard of care for this group of patients, and they are generally excluded or ineligible for clinical trials. Several effective novel agents have been licensed in recent years for the treatment of diffuse large b‐cell lymphoma (DLBCL), including CD19 CAR‐T cell therapy and CD3xCD20 bispecific antibody. Case Report Acknowledging the limited data and extrapolating the evidence from trials in DLBCL, we report a case of R/R PTLD successfully treated with CD3xCD20 bispecific antibody, Epcoritamab, with good tolerability and long‐term response. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haemato-Oncology The Royal Marsden NHS Foundation Trust Sutton UK.
ORCID-Profile: Li Yuan Chan, Dima El-Sharkawi
Zitieren
APA
Chan, L. Y., O'Connor, S., El-Sharkawi, D., & Iyengar, S. (2025). Epcoritamab for Relapsed/Refractory EBV+ Post‐Transplant Lymphoproliferative Disorder of DLBCL‐Type. eJHaem, 6(6). https://doi.org/10.1002/jha2.70156
Vancouver
Chan LY, O'Connor S, El-Sharkawi D, Iyengar S. Epcoritamab for Relapsed/Refractory EBV+ Post‐Transplant Lymphoproliferative Disorder of DLBCL‐Type. eJHaem. 2025;6(6). doi:10.1002/jha2.70156
BibTeX
@article{Chan2025,
author = {Chan, Li Yuan and O'Connor, Simon and El-Sharkawi, Dima and Iyengar, Sunil},
title = {Epcoritamab for Relapsed/Refractory EBV+ Post‐Transplant Lymphoproliferative Disorder of DLBCL‐Type},
journal = {eJHaem},
year = {2025},
volume = {6},
number = {6},
doi = {10.1002/jha2.70156}
}
EUVIMED